Revolutionizing nerve regeneration: A novel approach using polylactic acid/chitosan conduit with nerve-like cells and <i>Bacopa monnieri</i> in male rat model
Hoveizi E., Naddaf H., Naeimavi E.
Animal Study, published in Regen Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Regen Ther (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40487229
- PMCID
- PMC12144460
- DOI
- 10.1016/j.reth.2025.05.003
Abstract (original English)
Objectives This research aims to use neural-like cells (NLCs) derived from endometrial mesenchymal stem cells (EnMSCs) on a polylactic acid/chitosan scaffold (PLA/CS) along with the use of bacopa monnieri (Memocopa) in a rat sciatic nerve injury model for sciatic nerve regeneration. While previous studies have explored stem cell therapies and scaffold-based approaches for nerve regeneration, using EnMSCs in combination with a PLA/CS scaffold and Memocopa represents a novel, potentially synergistic approach. Method EnMSCs were isolated, characterized, and differentiated in a study. The expression of specific genes in the differentiated cells was confirmed using RT-PCR and immunocytochemistry. PLA nanofiber and chitosan hydrogel scaffolds were created for neural tissue engineering. Memocopa was administered orally alongside scaffold and cell transplantation. The study involved 25 adult male Wistar rats with a 3 mm sciatic nerve gap, divided into five groups based on treatment. Animals were monitored for 8 weeks, during which SFI was measured. Tissue samples were then prepared for histological examination, including various staining techniques. Results The combination of scaffold, cells, and Memocopa showed significant improvements in sciatic nerve function, as indicated by the SFI results in the eighth week: conduit group -33.87, conduit/cells group -25.92, conduit/cells/Memocopa
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.